All News
Biologic Persistence in Psoriatic Arthritis and Psoriasis
Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.
Read Article
Inflammatory Arthritis Spread by ATP and Neural Crosstalk
A novel study from the Journal of Experimental Medicine suggests that a reflex neural signaling at sites of inflammation may lead to spread to other inflammatory sites via and ATP-mediated neural crosstalk.
Read Article
Relevance of Raynaud’s in Systemic Sclerosis
Raynaud’s phenomenon (RP) is integral to the diagnosis and management of systemic sclerosis (SSc) patients; a recent analysis suggests that RP should be characterized based on color change and the presence of other symptoms to know whether RP portends more serious manifestations.
Read Article
RNL 2022: Spondyloarthritis Spectrum
This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.
- Microbiome in Spondyloathritis - Jose Scher, MD
- Axial Psoriatic Arthritis - Philip Mease, MD
- Juvenile Spondyloathritis - Pamela Weiss, MD
Read Article
Multimorbidity Burden in Rheumatoid Arthritis
Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.
Read Article
Acute Inflammatory Responses Needed to Resolve Chronic Pain
Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.
Read Article
Bimekizumab Development Delayed by FDA
UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).
Read Article
Links:
Links:
Links:
Methotrexate Monitoring (5.13.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.
Read Article
Can You Reduce Frequency of Methotrexate Monitoring?
Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an increase in adverse outcomes.
Read Article
Links:
Bimekizumab's Favorable Safety Profile in Psoriasis
A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.
Read Article
RNL 2022: Psoriatic Arthritis Advances
Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.
This webinar presented exerpts from these lectures along with audience Q & A
Read Article
Making You the Expert of You! (Smart Rules for Patients)
You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.
Read Article
Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis
Prevention of knee and hip osteoarthritis would obviate considerable disability and future surgery. We may be one step closer according to a prospective European GWAS study showing polygenic risk scores (PRSs) significantly associated with higher risks for knee and hip OA joint replacement.
Read Article
Diagnostic Delays in Spondyloarthritis Still Prolonged
Previously quoted average delay in diagnosing axial spondyloarthritis (axSpA) may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between five and six years.
Read Article
Links:
What is JAKne? (5.6.2022)
Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.
Read Article